Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Turmoil and tensions at FDA after dramatic exit of top drug regulator

Scramble to find replacement for George Tidmarsh shines light on dysfunction at US regulatory agency

The Guardian - US

This new eye drop could help adults with age-related vision issues

The drops specifically combat presbyopia, an age related blurry vision issue.

Axios

Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know

OxyContin maker Purdue Pharma's efforts to settle thousands of lawsuits over the toll of opioids is on the verge of approval

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight?

Cidara Therapeutics Inc. (NASDAQ:CDTX) shares are trending on Friday.

Benzinga

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

Dave Ricks, CEO of pharmaceutical giant Eli Lilly and Co. (NYSE:LLY), delivered a scathing critique of pharmacy benefit managers (PBMs), accusing the industry’s “middle actors” of “rent taking” and creating a “terrible incentive” structure that caused insulin list prices to skyrocket.

Benzinga

FDA Names Veteran Oncologist Richard Pazdur To Lead Drug Center After Ethics Scandal Ousts George Tidmarsh

The U.S. Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur as the new head of its drug center, succeeding Dr. George Tidmarsh, who was removed following an ethics complaint just months after his appointment.

Benzinga

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India

Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share.

Benzinga

Pfizer Metsera Acquisition: What It Means for Patients and the Future of Weight Loss

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with next-generation medicines.

International Business Times UK

Organon Cuts 2025 Sales Outlook Despite Earnings Beat

Organon (NYSE:OGN) reported third-quarter adjusted earnings of $1.01 per share on Monday, beating the consensus estimate of 94 cents. The global healthcare company reported quarterly sales of $1.602 billion, beating the Wall Street estimate of $1.56 billion.

Benzinga

Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Nasdaq Composite gaining more than 400 points on Monday.

Benzinga

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk

The Independent UK

Why Is Clearmind Stock Down Today?

Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are falling Friday after the clinical-stage biotech company shared a key update about its stock listing.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch

Pelthos Therapeutics Inc. (NYSE:PTHS) on Friday acquired the U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. (NASDAQ:BFRI) and Ferrer Internacional S.A.

Benzinga

Becton Dickinson Sees High Single-Digit Profit Growth Ahead, Plans Share Buybacks From Waters Deal

Becton Dickinson and Co (NYSE:BDX) reported fourth-quarter adjusted earnings of $3.96, beating the consensus of $3.92.

Benzinga

AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the consensus of $14.80 billion, driven by double-digit growth in oncology, CVRM, and biopharmaceuticals.

The Guardian - UK

NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

Pascal Soriot calls for cost-effectiveness thresholds to undergo ‘substantial adjustment based on inflation’

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection

Biohaven Ltd. (NYSE:BHVN) stock plummeted on Wednesday, reaching its 52-week low, according to data from Benzinga Pro.

Evening Standard

US ambassador warns pharma firms will quit UK if NHS does not pay more for drugs

Donald Trump’s man in London reiterated the US president’s demands for the UK to pay pharmaceutical companies more money.

Benzinga

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Stanley Druckenmiller's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billionaire investor's family office took a fresh position in VKTX during the second quarter, buying roughly 549,000 shares at an average price of $25.33.…

International Business Times

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

Benzinga

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion.

The Guardian - UK

Ozempic maker struggles as it loses ground to rivals in weight-loss market

Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli Lilly

Benzinga

Cryoport Reports Strong Q3 Results, Raises FY25 Outlook

Cryoport Inc (NASDAQ:CYRX) reported third-quarter financial results after the market close on Tuesday. Here’s a rundown of the temperature-controlled supply chain solutions company’s report.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.